Zepbound
What is Zepbound?
Zepbound is the newest anti-obesity medication on the market. Zepbound received the FDA indication for the treatment of obesity and overweight status with weight-related medical conditions on November 8th, 2023. Zepbound (generic name Tirzepatide) is manufactured by the pharmaceutical company Eli Lilly. It is the first dual combination incretin peptide to get FDA approval for obesity and weight loss. While Zepbound is indicated for weight loss, Mounjaro (the other branding of Tirzepatide) is indicated for the treatment of type 2 diabetes.
Why choose Zepbound and Medical Weight Loss at La Chele?
La Chele is the Premier Medical Aesthetics Provider in the tri-state area, and has been offering a comprehensive Lifestyle Medical Weight Loss Program for years. We offer consultations and treatment with our Double-Board Certified Bariatric Weight Loss Physician, Erin Saltzman, MD, and with the head of our Wellness Department and Hormone Therapy, Maureen McSorley, FNP-C, who are both experts in Medical Weight Loss.
Our program is different from other programs in that we offer a comprehensive InBody analysis with our state-of-the-art scale, a personalized diet and exercise program, continued check-ins with our Providers, metabolic lab evaluation, and prescriptive weight loss medication.
We have seen incredible and life-changing results with our weight loss program. Our Providers’ continued support is essential for any peaks and valleys you may experience; our team is always here to consult with you and work through the program to set you up for continued success.
What is Zepbound used for?
Zepbound is indicated for the treatment of obesity and overweight status with weight-related medical conditions.
How does Zepbound work?
Operating as a dual-agonist drug, Zepbound triggers the activation of GIP and GLP-1 hormone receptors. Activation of these receptors in the hunger center of the brain increases satiety and decreases hunger. Activation of these receptors in the gastrointestinal tract causes slowing of gastric emptying and slowing of food transit through the intestines. Zepbound also improves the sensitivity of insulin, which helps to optimize blood sugars and decrease visceral fat stores.
How is Zepbound administered?
Zepbound is administered by injecting the medication from a prefilled pen, under the skin, one time per week.
What are the side effects of Zepbound?
The common side effects of Zepbound are similar to those that patients have experienced with Mounjaro, Wegovy and Ozempic. The most common side effects include decreased appetite, nausea, vomiting, diarrhea, constipation and abdominal pain. These potential side effects can be minimized by starting at a low dose and titrating the dose as tolerated by the patient.
How long does it take for Zepbound to start working?
Zepbound starts working within a few days of the first dose. Most patient feel appetite suppression within the first few days and achieve notable weight loss within the first few weeks.
How much does Zepbound cost?
The cost of Zepbound depends on insurance coverage. Most insurance companies require a prior-authorization to approve coverage for Zepbound. Insurance coverage qualifications generally include a BMI greater than / equal to 30 or greater than / equal to 27 with a weight-related medical condition. If you do not have coverage for Zepbound, your La Chele Provider can help to find the most economic way to pay for Zepbound out-of-pocket.
What are the benefits of taking Zepbound?
Zepbound has many health benefits including weight loss, treatment of insulin resistance and type 2 diabetes, improvement of fatty liver, and prevention of cardiovascular disease.
Is Zepbound safe to use for weight loss?
Yes. Under the supervision of a qualified medical provider, Zepbound is safe to use for weight loss.
What is the difference between all weight loss drugs?
Zepbound and Mounjaro (both Tirzepatide) are dual incretin peptide drugs activating GLP-1 and GIP receptors. Wegovy and Ozempic (both Semaglutide) are GLP-1 receptor agonists. Zepbound and Wegovy are indicated for the treatment of obesity and overweight status with weight-related medical conditions. Mounjaro and Ozempic are indicated for the treatment of type 2 diabetes. There are several other non-incretin (peptide) weight loss medications available including Contrave (Bupropion + Naltrexone) and Qsymia (Phentermine + Topiramate).
Your La Chele provider will determine the most effective medication regimen for you.
Get started today!
Book a consultation in our New Hope, Newtown, Upper Dublin, or Ellis Preserve locations here! Or call us at (855)-522-4353